IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

2024.01.18
Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high risk of recurrence following curative resection or ablation. The study's principal investigator, Professor Pierce Chow of the National Cancer Centre Singapore, revealed the trial's results, suggesting a potential paradigm shift in the management of high-risk HCC patients.
IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

IMbrave050 trial results: Atezolizumab combined with bevacizumab can significantly improve RFS in patients with HCC at high risk of recurrence

2023.10.13
Recent findings from the phase III IMbrave050 trial presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting have unveiled a significant advancement in the treatment of hepatocellular carcinoma (HCC). The trial investigated the impact of adjuvant therapy with atezolizumab in combination with bevacizumab on recurrence-free survival (RFS) in HCC patients at high risk of recurrence following curative resection or ablation. The study's principal investigator, Professor Pierce Chow of the National Cancer Centre Singapore, revealed the trial's results, suggesting a potential paradigm shift in the management of high-risk HCC patients.